Background
==========

Globally, gastric cancer ranks fifth and third in cancer incidence and mortality, respectively. There were more than 1.03 million newly diagnosed gastric cancer cases worldwide and approximately 783,000 death cases in 2018. Gastric cancer morbidity is the highest in eastern Asia \[[@b1-medscimonit-26-e923931]\]. Distant metastases to gastric cancer are common at the time of diagnosis \[[@b2-medscimonit-26-e923931]\]. Metastatic disease is found at the initial diagnosis of 35% to 40% of gastric cancer patients, and 4% to 14% of these have metastatic disease in the liver, followed by the lung, bone, and brain \[[@b3-medscimonit-26-e923931],[@b4-medscimonit-26-e923931]\]. Many factors such as age, tumor location, tumor size, TNM (Tumor-Node-Metastasis), and surgery, affect the prognosis of cancer.

At present, the prognosis of solid cancer is decided by the American Joint Committee on Cancer (AJCC) TNM staging system \[[@b5-medscimonit-26-e923931],[@b6-medscimonit-26-e923931]\]. However, the existing TNM staging does not reflect tumor prognosis well \[[@b7-medscimonit-26-e923931],[@b8-medscimonit-26-e923931]\]. Based on this system, we cannot evaluate the prognosis between patients with stage IV gastric cancer. Therefore, we need to develop a new prognosis prediction model to accurately individualize the early mortality between advanced cancer patients. Large sample studies have been rarely performed, and are urgently needed at present.

This study was based on information about patients with stage IV gastric cancer from the Surveillance, Epidemiology, and End Results (SEER) database to analyze demographic and clinical characteristics, evaluate early mortality, and examine the risk factors of early death when first diagnosed. In addition, the work has produced a predictive nomogram that contained relevant factors for predicting early mortality and internal validation was performed to test the accuracy of the predictive model.

Material and Methods
====================

Data
----

Data was obtained from the SEER database, which provides the cancer relevant factors and survival outcomes from established cancer registries across approximately one-third of the United States population. The database includes information about the clinical characteristics and survival outcomes for different cancer patients. It has certain standards for patient data collection, therefore, its accuracy is guaranteed. SEER\*Stat Software version 8.3.5 (*<https://seer.cancer.gov/seerstat/>*, National Cancer Institute, Maryland, U.S.) was used to collect information about gastric cancer patients in the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The SEER Program collects data from population-based cancer registries with anonymous information. The SEER database has public-use data and our study did not require approval or a declaration of local ethics.

Study population
----------------

This was a population-based cohortstudy. The SEER database did not collect data on organ metastases until 2010. Therefore, the study included patients diagnosed with gastric cancer between 2010 and 2016 (with at least 3 months follow-up). Patients with non-primary tumors, T0, Tis, M0, dead at diagnosis, ambiguous survival time, unknown cause of death, failed to be followed up, or ≤18 years old were excluded. Inclusion criteria were patients with stage IV gastric cancer confirmed at the initial diagnosis ([Figure 1](#f1-medscimonit-26-e923931){ref-type="fig"}). When cancer patients died within 3 months of initial diagnosis, it was defined as early death \[[@b9-medscimonit-26-e923931],[@b10-medscimonit-26-e923931]\].

Statistical analysis
--------------------

The quantitative data involved in the study were described as mean±standard deviation and comparisons between different groups were analyzed using Student's *t* tests. The categorical data were mainly described as a percentage (%) and the difference between categorical variables were analyzed by the Pearson chi-squared test. The primary outcomes were total early death, cancer-specific early death, and non-cancer-specific early death. Non-cardia includes the fundus of the stomach, body of the stomach, lesser curvature of the stomach, greater curvature of the stomach, overlapping lesion of the stomach, gastric antrum, and pylorus. Influences of the correlative factors on survival time were compared by the Kaplan-Meier method, and the log-rank test was used. The study first used univariate logistic regression to derive factors related to early death. Then variables with p\<0.05 were included in multivariate logistic regression. Incomplete information in the variables was excluded.

The predictive nomograms for total early mortality, and cancer-specific early mortality were based on the results of regression analysis using the R version 3.6.1 (Lucent Technologies, New Jersey, U.S.). Calibration plots for the nomograms were produced. The reliability of the nomograms was evaluated by the C-index, receiver operating characteristic curve, the area under the curve (AUC), and decision curve analysis (DCA). Due to the lack of relevant models for the early death prognosis of patients with stage IV gastric cancer, the nomogram and internal verification with the existing prognostic criterion could not be compared.

Results
=======

Demographic and clinical characteristics
----------------------------------------

Information was initially collected from the database for 47,553 gastric cancer patients, and 11,036 eligible patients were included in the study after strict screening for inclusion and exclusion criteria. The average age of patients was 63.60±14.28 years, with 64.2% (N=7081) male and 35.8% (N=3955) female patients. The average age of females with gastric cancer was higher than that of males (64.10±15.76 years *vs.* 63.32±13.38 years, p\<0.001). The majority of patients were Caucasians (71.7%, N=7911), 56.3% patients (N=6208) were married, 32.2% patients had cardia gastric cancer, and 88.0% patients had adenocarcinomas. Among the study population, the percentages of liver, lung, bone and brain metastases were 43.0%, 14.7%, 12.8%, and 2.0%, respectively. Patients' clinical characteristics are shown in [Table 1](#t1-medscimonit-26-e923931){ref-type="table"}.

Incidence of early death
------------------------

In the present study, 4932 (44.7%) gastric cancer patients had total early deaths, where 4697 (42.6%) patients died of the cancer and 235 (2.1%) patients died of other reasons. Early mortality for males with gastric cancer was higher than females, however, there was no statistical difference (28.6% *vs.* 16.1%, χ^2^=0.19, p\>0.05). The incidence of total early death fluctuated significantly with age. Early mortality in patients aged 18--40 years decreased with age, while early mortality increased for the other age groups. Trends in early mortality were roughly the same for males and females in the various age groups ([Figure 2A](#f2-medscimonit-26-e923931){ref-type="fig"}).

Early mortality varied with the location of primary tumors. In females, the lowest early mortality was for tumors in the lesser curvature of the stomach (38.6%), followed by the body of the stomach (39.7%) and cardia (40.3%). However, the tumors of the greater curvature of the stomach (49.1%) and fundus of the stomach (48.6%) contributed to higher early mortality. In males, the lowest early mortality was seen in patients with tumors in the cardia (37.8%). However, patients with tumors in the greater curvature of the stomach (52.0%), overlapping lesion of the stomach (48.5%), and body of the stomach (48.1%) contributed to higher early mortality. The cardia cancer (38.3%) presented significantly lower early mortality than the non-cardia cancer (45.0%) (χ^2^=38.98, p\< 0.001) ([Figure 2B](#f2-medscimonit-26-e923931){ref-type="fig"}).

Gastric cancer patients with brain metastases had the highest early mortality (59.0%), followed by lung (53.8%), bone (52.4%), and liver metastases (49.6%). In females, early mortality due to brain metastases (68.3%) was higher than that in males (55.4%) and the total group (59.0%) ([Figure 2C](#f2-medscimonit-26-e923931){ref-type="fig"}).

The early mortality of gastric cancer patients was positively correlated with the number of metastatic organ sites (χ^2^=164.29, p\<0.001). Male patients presented with similar results (χ^2^=81.435, p\<0.001). For males, early mortality in four organ metastases (66.7%) was higher than three organ metastases (58.9%). However, for females, early mortality in four organ metastases (60.0%) was slightly lower than three organ metastases (61.1%) ([Figure 2D](#f2-medscimonit-26-e923931){ref-type="fig"}).

The median survival time of different age groups varied. Patients older than 85 years had the shortest median survival time (p\<0.001) compared with the other listed age groups ([Figure 3A](#f3-medscimonit-26-e923931){ref-type="fig"}). Amongst the study population, the median survival time of non-cardia cancer was significantly shorter than patients with cardia gastric cancer (p\<0.001) ([Figure 3B](#f3-medscimonit-26-e923931){ref-type="fig"}). Patients with liver metastases had significantly shorter survival times than patients without liver metastases. Similar results were seen for lung metastases (p\<0.001) ([Figure 3C, 3D](#f3-medscimonit-26-e923931){ref-type="fig"}). Compared to patients with a lower histological grade, those with a higher histological grade had worse survival prognosis (p\<0.001) ([Figure 3E](#f3-medscimonit-26-e923931){ref-type="fig"}). Surgical treatment significantly extended patients' survival time (p\<0.001) ([Figure 3F](#f3-medscimonit-26-e923931){ref-type="fig"}).

Factors associated with early death
-----------------------------------

Univariate logistic regression showed advanced age, marital status, higher T stages, and liver, and lung metastases were all closely related to the total early death, cancer-specific early death and non-cancer-specific early death. Poor differentiation, higher N stages, bone metastases, and surgery were only related to total early death and cancer-specific early death ([Table 1](#t1-medscimonit-26-e923931){ref-type="table"}).

After incorporating the significant factors into multivariable logistic regression, the results showed that advanced age, primary site, poor differentiation, liver metastases, lung metastases, and surgery were significantly related to total early death. While tumor size, poor differentiation, liver metastases, and surgery were only significantly related to cancer-specific early death. Poor differentiation, liver metastases, and surgery were significantly related to total early death and cancer-specific early death ([Table 2](#t2-medscimonit-26-e923931){ref-type="table"}).

Establishment of nomograms for predicting early mortality
---------------------------------------------------------

Based on the previously mentioned factors (age, primary site, tumor size, histological grade, liver metastases, lung metastases, surgery) according to the multivariable model, significant factors related to non-cancer-specific early death were insufficient, only two nomograms were established to predict total early mortality, and cancer-specific early mortality among stage IV gastric cancer patients, respectively. The probability of total early death ranged from 0.05 to 0.90, while cancer-specific early death ranged from 0.10 to 0.95. Therefore, not every total score would have a corresponding probability. The line for the histological grade was the longest in the two prediction models, suggesting that histological grade had the most value in predicting early mortality. In the nomogram for predicting cancer-specific early mortality, surgery and T stage also had great predictive value ([Figure 4A, 4B](#f4-medscimonit-26-e923931){ref-type="fig"}). Internal verification showed that the C-index for the total early mortality nomogram was 0.627 and cancer early mortality was 0.656. The solid lines of the calibration curves approach at a 45°, suggesting accurate prediction by these two models. ([Figure 5A, 5B](#f5-medscimonit-26-e923931){ref-type="fig"}). Moreover, the AUC for the two nomograms were 73.5%, and 68.0%, respectively, exhibiting good discrimination ([Figure 5C, 5D](#f5-medscimonit-26-e923931){ref-type="fig"}). The DCA also proved the value of the two models. The net benefit of our risk models were larger than that in other two scenarios (all screening or none-screening) in a wide range of threshold probabilities ([Figure 6A, 6B](#f6-medscimonit-26-e923931){ref-type="fig"}).

Discussion
==========

Gastric cancer is one of the main causes of cancer death worldwide \[[@b1-medscimonit-26-e923931]\]. It has been proposed that patients with stage IV gastric cancer have pessimistic survival time. Qiu et al. reported that median survival time for them was less than 4 months \[[@b11-medscimonit-26-e923931]--[@b13-medscimonit-26-e923931]\]. From the 11,036 patients included in this study, 42.6% succumbed to the disease within three months after the initial diagnosis. Therefore, knowledge of the factors (age, primary site, tumor size, histological grade, liver metastases, lung metastases, surgery) that affect the early death of patients can help formulate corresponding therapeutic schemes in advance, to improve the survival rate. To the best our knowledge, this study is the first to explore early death prediction for patients with stage IV gastric cancer.

In this study, some factors were found to be positively related to early mortality in stage IV gastric cancer, including advanced age, non-cardia, high histological grade (grade III, IV), tumor size, and distant metastases (liver and lung). Surgery on primary sites was negatively related to early death.

Previous studies reported advanced age as one of the risk factors affecting the prognosis of gastric cancer. Compared with younger patients, the survival time of elderly patients is significantly shorter \[[@b14-medscimonit-26-e923931],[@b15-medscimonit-26-e923931]\]. Our study showed that the early death rate roughly increased when patients were older than 40, for males and females. The link between advanced age and early death had also been explored. Elderly patients always have a higher incidence of serious complications, weak immune systems, and muscle atrophy is related to poor prognosis and early death \[[@b16-medscimonit-26-e923931]--[@b18-medscimonit-26-e923931]\]. Young patients are in better basic physical condition and have fewer comorbidities, such as heart disease, high blood pressure, etc. and are more likely to tolerate the side effects of adjuvant therapy \[[@b19-medscimonit-26-e923931]\]. Compared to elderly patients, young patients are more willing to try other treatments \[[@b16-medscimonit-26-e923931],[@b20-medscimonit-26-e923931]\]. However, the early death rate among patients aged 18-40 years declined with age. Another study analyzed a group of young patients aged 30 years or younger with unique clinicopathological features such as advanced stage cancer, a positive family history of cancer, undifferentiated and diffuse histologic type. Based on the aforementioned factors, their prognosis would be relatively poorer than others \[[@b21-medscimonit-26-e923931]\].

A series of studies investigated the differences between cardia gastric cancer and non-cardia gastric cancer. They concluded that cardia gastric cancer patients were generally considered to have worse prognosis than the patients with non-cardia gastric cancer because of the different clinicopathological features \[[@b22-medscimonit-26-e923931]--[@b24-medscimonit-26-e923931]\]. In general, cardia gastric cancer was assumed to have more aggressive biological behavior and was more prone to lymph node metastasis and recurrence \[[@b25-medscimonit-26-e923931]\]. However, in our study, cardia gastric cancer was less likely to cause early death than non-cardia gastric cancer. This result is contradictory and we investigated the cause for this result. The previous study reported that the five-year survival rates of patients with cardia gastric cancer who underwent R0 resection were no lower than those with non-cardia cancer \[[@b24-medscimonit-26-e923931]\]. Patients found to have lymph node metastases would be more likely to undergo lymphadenectomy. Therefore, other adjuvant therapies and R0 resection may influence the result. The relatively small sample of the cardia gastric cancer group in the present study may be another potential reason. Because other factors associated with early death, such as age, primary site, tumor size, histological grade, etc. can greatly interfere with the result.

Tumor size, considered to be the largest diameter of a solid tumor, is another important clinical indicator of prognoses \[[@b26-medscimonit-26-e923931]\], which can be accurately obtained by gastroscopy or imaging. This parameter has also been confirmed as an independent prognostic factor in solid cancers \[[@b27-medscimonit-26-e923931]--[@b29-medscimonit-26-e923931]\]. It is often used as an indicator to decide whether surgery is needed. Tumor size has been incorporated into the TNM staging systems to assess the prognosis, such as non-small-cell lung cancer \[[@b30-medscimonit-26-e923931]\]. The optimal cutoff value for tumor size was 4 cm. Large tumor sizes often indicated poor prognoses, which was consistent with the result of this study \[[@b31-medscimonit-26-e923931]\].

Liver and lung metastases were related to unfavorable prognoses in gastric cancer patients as vital organ damage and tumor load increase to lethal levels \[[@b11-medscimonit-26-e923931]\]. The median survival time for gastric cancer patients with liver metastases was 2--3 months and 0--10% patients can survive longer than 5 years \[[@b32-medscimonit-26-e923931]\]. While only 2--4% patients with lung metastases can survive longer than 5 years\[[@b33-medscimonit-26-e923931]\]. This study also found that early death was associated with liver and lung metastasis. In addition, a positive correlation between prognosis and the number of metastatic organs was seen.

Stage IV gastric cancer patients already had distant metastasis, and the need for surgery remains controversial. Previous National Comprehensive Cancer Network guidelines suggest that for patients with distant metastasis, surgery can only be used as a means of palliative treatment. Previous studies have shown that for patients with advanced gastric cancer, the survival benefits of undergoing surgical treatment compared to no surgery are obvious. However, the option of surgery needs to be treated with caution and more rigorous research should be conducted in the future to explore the impact of surgery on patients with distant organ metastases \[[@b14-medscimonit-26-e923931],[@b34-medscimonit-26-e923931]\].

The Cox regression model was also used in our research. We incorporated meaningful values (p\<0.05) from the multivariate Cox regression model to construct nomograms for early mortality and cancer early mortality. However, upon verification of the calibration curve, we found that the solid line of the curve did not approach in the direction of 45°. Therefore, the logistic regression model was chosen for establishment of the nomogram ([Supplementary Table 1](#s1-medscimonit-26-e923931){ref-type="supplementary-material"}, [Supplementary Figures 1](#s2-medscimonit-26-e923931){ref-type="supplementary-material"}, [2](#s3-medscimonit-26-e923931){ref-type="supplementary-material"}).

Limitations
-----------

There are several limitations in our study. Firstly, our study only included patients who were initially diagnosed with stage IV gastric cancer, and patients who subsequently developed metastases were not included. The SEER database includes approximately 30% of the total US population only, therefore, the research sample is not extensive enough. Secondly, some factors related to gastric cancer have not been explored and may affect the predictive ability of the nomogram, such as helicobacter pylori, sarcopenia, cachexia, some inflammatory indices, and the Eastern Cooperative Oncology Group performance score. Further studies need to be conducted with consideration of these factors related to gastric cancer. Thirdly, only an internal validation of the nomogram was performed, and external verification is still necessary. We will do our best to validate this prognostic model in future clinical practice.

Conclusions
===========

Based on the aforementioned factors (age, primary site, tumor size, histological grade, liver metastases, lung metastases, surgery), a predictive nomogram was set up. It has a good ability to predict early mortality in patients with stage IV gastric cancer. This model can be widely used in clinical practice, allowing clinicians to develop more personalized treatments for patients with advanced gastric cancer, to give them the best possible prognosis.

Supplementary Data
==================

###### 

Multivariable Cox regression for analyzing the risk factors for early death.

  Factors                                     Total early death        Cancer-specific early death   Non-cancer-specific early death                                    
  ------------------------------------------- ------------------------ ----------------------------- --------------------------------- --------- ---------------------- ---------
  **Age**                                                                                                                                                               
   ≤55                                        Ref                      1                             Ref                               1         Ref                    1
   56--65                                     0.853 (0.481--1.513)     0.587                         0.917 (0.707--1.188)              0.510     1.472 (0.877--2.472)   0.144
   66--75                                     2.625 (1.601--4.302)     \<0.001                       1.586 (1.210--2.079)              \<0.001   3.138 (1.938--5.083)   \<0.001
   ≥76                                        2.532 (1.534--4.179)     \<0.001                       1.461 (1.106--1.930)              0.008     3.790 (2.328--6.172)   \<0.001
  **Race**                                                                                                                                                              
   White                                      Ref                      1                             Ref                               1         Ref                    1
   Black                                      1.031 (0.644--1.652)     0.898                         NS                                NS        NS                     NS
   Asian or Pacific Islander                  0.627 (0.400--0.981)     0.041                         NS                                NS        NS                     NS
   American Indian/Alaska Native              1.563 (0.314--7.778)     0.585                         NS                                NS        NS                     NS
   Unknown                                    NA                       NA                            NA                                NA        NA                     NA
  **Sex**                                                                                                                                                               
   Female                                     Ref                      1                             Ref                               1         Ref                    1
   Male                                       NS                       NS                            NS                                NS        NS                     NS
  **Marital status**                                                                                                                                                    
   Unmarried                                  Ref                      1                             Ref                               1         Ref                    1
   Married                                    0.750 (0.532--1.056)     0.099                         0.992 (0.814--1.209)              0.934     0.808 (0.592--1.103)   0.180
   Unknown                                    NA                       NA                            NA                                NA        NA                     NA
  **Insurance status**                                                                                                                                                  
   Uninsured                                  Ref                      1                             Ref                               1         Ref                    1
   Insured                                    1.710 (0.618--4.731)     0.301                         1.172 (0.769--1.786)              0.460     1.575 (0.577--4.297)   0.375
   Unknown                                    NA                       NA                            NA                                NA        NA                     NA
  **Primary site**                                                                                                                                                      
   Non-cardia                                 Ref                      1                             Ref                               1         Ref                    1
   Cardia                                     0.336 (0.171--0.660)     0.002                         0.832 (0.623--1.113)              0.215     NS                     NS
   Unknown                                    NA                       NA                            NA                                NA        NA                     NA
  **Pathological type**                                                                                                                                                 
   Adenocarcinoma(exclude signet ring cell)   Ref                      1                             Ref                               1         Ref                    1
   Signet ring cell                           NS                       NS                            0.968 (0.761--1.231)              0.791     0.808 (0.538--1.213)   0.304
   Others                                     NA                       NA                            NA                                NA        NA                     NA
  **Tumor size (cm)**                                                                                                                                                   
   \<3                                        Ref                      1                             Ref                               1         Ref                    1
   ≥3 \<5                                     0.998 (0.530--1.878)     0.994                         1.513 (1.046--2.191)              0.028     NS                     NS
   ≥5 \<7                                     0.745 (0.422--1.497)     0.477                         1.259 (0.873--1.815)              0.218     NS                     NS
   ≥7 \<9                                     1.093 (0.563--2.121)     0.792                         1.380 (0.932--2.042)              0.108     NS                     NS
   ≥9                                         1.020 (0.531--1.961)     0.953                         1.237 (0.831--1.843)              0.295     NS                     NS
   Unknown                                    NA                       NA                            NA                                NA        NA                     NA
  **T stage**                                                                                                                                                           
   T1                                         Ref                      1                             Ref                               1         Ref                    1
   T2                                         0.404 (0.107--1.524)     0.181                         0.842 (0.436--1.626)              0.609     0.767 (0.408--1.442)   0.410
   T3                                         0.876 (0.399--1.922)     0.741                         1.394 (0.843--2.306)              0.195     0.735 (0.484--1.119)   0.151
   T4                                         1.273 (0.590--2.750)     0.539                         1.825 (1.091--3.055)              0.022     1.065 (0.736--1.541)   0.739
   Others                                     NA                       NA                            NA                                NA        NA                     NA
  **Lymphatic metastasis**                                                                                                                                              
   N0                                         Ref                      1                             Ref                               1         Ref                    1
   N1                                         0.943 (0.543--1.637)     0.834                         0.888 (0.626--1.259)              0.504     NS                     NS
   N2                                         0.897 (0.493--1.632)     0.723                         1.284 (0.912--1.807)              0.152     NS                     NS
   N3                                         0.971 (0.574--1.643)     0.913                         1.343 (0.972--1.857)              0.074     NS                     NS
   Others                                     NA                       NA                            NA                                NA        NA                     NA
  **Histological grade**                                                                                                                                                
   I                                          Ref                      1                             Ref                               1         Ref                    1
   II                                         3.265 (0.428--24.917)    0.254                         1.338 (0.556--3.219)              0.515     NS                     NS
   III                                        5.162 (0.692--38.548)    0.109                         1.781 (0.749--4.237)              0.192     NS                     NS
   IV                                         8.019 (0.945--68.084))   0.056                         2.669 (0.989--7.202)              0.053     NS                     NS
   Others                                     NA                       NA                            NA                                NA        NA                     NA
  **Liver metastases**                                                                                                                                                  
   Yes                                        Ref                      1                             Ref                               1         Ref                    1
   No                                         0.496 (0.347--0.711)     \<0.001                       0.696 (0.560--0.866)              0.001     NS                     NS
   Others                                     NA                       NA                            NA                                NA        NA                     NA
  **Lung metastases**                                                                                                                                                   
   Yes                                        Ref                      1                             Ref                               1         Ref                    1
   No                                         0.334 (0.196--0.568)     \<0.001                       0.457 (0.305--0.685)              \<0.001   0.665 (0.446--0.992)   0.045
   Others                                     NA                       NA                            NA                                NA        NA                     NA
  Bone metastases                                                                                                                                                       
   Yes                                        Ref                      1                             Ref                               1         Ref                    1
   No                                         0.795 (0.336--1.881)     0.601                         0.650 (0.399--1.060)              0.084     NS                     NS
   Others                                     NA                       NA                            NA                                NA        NA                     NA
  **Brain metastases**                                                                                                                                                  
   Yes                                        Ref                      1                             Ref                               1         Ref                    1
   No                                         0.503 (0.119--2.129)     0.351                         0.657 (0.282--1.530)              0.330     NS                     NS
   Others                                     NA                       NA                            NA                                NA        NA                     NA
  **Surgery**                                                                                                                                                           
   Yes                                        Ref                      1                             Ref                               1         Ref                    1
   No                                         2.920 (1.363--6.255)     0.006                         4.654 (2.874--7.536)              \<0.001   NS                     NS
   Unknown                                    NA                       NA                            NA                                NA        NA                     NA

Ref -- reference; OR -- odds ratio; NA -- not available; NS -- not significant.

###### 

Nomogram for predicting all causes of early mortality (**A**) and cancer-specific early mortality in stage IV gastric cancer patients (**B**).

###### 

The calibration curve for assessing the calibration of the nomogram in predicting all causes of early mortality (**A**) and cancer-specific early mortality (**B**).
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###### 

Univariable logistic regression for analyzing the risk factors for early death.

  Factors                                     Patients no.(%)                                 
  ------------------------------------------- ----------------- -------------- -------------- -------------
  **Age**                                                                                     
   ≤55                                        2040 (33.42)      1022 (20.72)   992 (21.12)    30 (12.77)
   56--65                                     1793 (29.37)      1181 (23.95)   1126 (23.97)   55 (23.40)
   66--75                                     1365 (22.36)      1203 (24.39)   1134 (24.14)   69 (29.36)
   ≥76                                        906 (14.84)       1526 (30.94)   1445 (30.76)   81 (34.47)
  **Race**                                                                                    
   White                                      4382 (71.79)      3529 (71.55)   3362 (71.58)   167 (71.06)
   Black                                      766 (12.55)       717 (14.54)    677 (14.41)    40 (17.02)
   Asian or Pacific Islander                  863 (14.14)       603 (12.23)    576 (12.26)    27 (11.49)
   American Indian/Alaska Native              69 (1.13)         66 (1.34)      65 (1.38)      1 (0.43)
   Unknown                                    24 (0.39)         17 (0.34)      17 (0.36)      0 (0.00)
  **Sex**                                                                                     
   Female                                     2176 (35.65)      1779 (36.07)   1697 (36.13)   82 (34.89)
   Male                                       3928 (64.35)      3153 (63.93)   3000 (63.87)   153 (65.11)
  **Marital status**                                                                          
   Unmarried                                  2086 (34.17)      2228 (45.17)   2120 (45.14)   108 (45.96)
   Married                                    3718 (60.91)      2490 (50.49)   2375 (50.56)   115 (48.94)
   Unknown                                    300 (4.91)        214 (4.34)     202 (4.30)     12 (5.11)
  **Insurance status**                                                                        
   Uninsured                                  280 (4.59)        290 (5.88)     284 (6.05)     6 (2.55)
   Insured                                    5706 (93.48)      4520 (91.65)   4300 (91.55)   220 (93.62)
   Unknown                                    118 (1.93)        122 (2.47)     113 (2.41)     9 (3.83)
  **Primary site**                                                                            
   Non-cardia                                 2912 (47.71)      2387 (48.40)   2270 (48.33)   117 (49.79)
   Cardia                                     2194 (35.94)      1364 (27.66)   1300 (27.68)   64 (27.23)
   Unknown                                    998 (16.35)       1181 (23.95)   1127 (23.99)   54 (22.98)
  **Pathological type**                                                                       
   Adenocarcinoma(exclude signet ring cell)   4083 (66.89)      3235 (65.59)   3078 (65.53)   157 (66.81)
   Signet ring cell                           1381 (22.62)      1011 (20.50)   970 (20.65)    41 (17.45)
   Others                                     640 (10.48)       686 (13.91)    649 (13.82)    37 (15.74)
  **Tumor size (cm)**                                                                         
   \<3                                        450 (7.37)        256 (5.19)     243 (5.17)     13 (5.53)
   ≥3 \<5                                     740 (12.12)       454 (9.21)     429 (9.13)     25 (10.64)
   ≥5 \<7                                     717 (11.75)       447 (9.06)     428 (9.11)     19 (8.09)
   ≥7 \<9                                     358 (5.87)        221 (4.48)     209 (4.45)     12 (5.11)
   ≥9                                         335 (5.49)        262 (5.31)     251 (5.34)     11 (4.68)
   Unknown                                    3504 (57.40)      3292 (66.75)   3137 (66.79)   155 (65.96)
  **T stage**                                                                                 
   T1                                         962 (15.76)       780 (15.82)    730 (15.54)    50 (21.28)
   T2                                         333 (5.46)        168 (3.41)     162 (3.45)     6 (2.55)
   T3                                         1029 (16.86)      454 (9.21)     431 (9.18)     23 (9.79)
   T4                                         1325 (21.71)      973 (19.73)    931 (19.82)    42 (17.87)
   Others                                     2455 (40.22)      2557 (51.85)   2443 (52.01)   114 (48.51)
  **Lymphatic metastasis**                                                                    
   N0                                         1979 (32.42)      1860 (37.71)   1766 (37.60)   94 (40.00)
   N1                                         2272 (37.22)      1438 (29.16)   1368 (29.12)   70 (29.79)
   N2                                         447 (7.32)        199 (4.03)     189 (4.02)     10 (4.26)
   N3                                         489 (8.01)        219 (4.44)     210 (4.47)     9 (3.83)
   Others                                     917 (15.02)       1216 (24.66)   1164 (24.78)   52 (22.13)
  **Histological grade**                                                                      
   I                                          125 (2.05)        55 (1.12)      52 (1.11)      3 (1.28)
   II                                         1166 (19.10)      714 (14.48)    667 (14.20)    47 (20.00)
   III                                        3494 (57.24)      2698 (54.70)   2593 (55.21)   105 (44.68)
   IV                                         68 (1.11)         76 (1.54)      74 (1.58)      2 (0.85)
   Others                                     1251 (20.49)      1389 (28.16)   1311 (27.91)   78 (33.19)
  **Liver metastases**                                                                        
   Yes                                        2392 (39.19)      2351 (47.67)   2231 (47.50)   120 (51.06)
   No                                         3464 (56.75)      2372 (48.09)   2268 (48.29)   104 (44.26)
   Others                                     248 (4.06)        209 (4.24)     198 (4.22)     11 (4.68)
  **Lung metastases**                                                                         
   Yes                                        751 (12.30)       873 (17.70)    825 (17.56)    48 (20.43)
   No                                         5028 (82.37)      3720 (75.43)   3547 (75.52)   173 (73.62)
   Others                                     325 (5.32)        339 (6.87)     325 (6.92)     14 (5.96)
  Bone metastases                                                                             
   Yes                                        672 (11.01)       741 (15.02)    714 (15.20)    27 (11.49)
   No                                         5144 (84.27)      3881 (78.69)   3690 (78.56)   191 (81.28)
   Others                                     288 (4.72)        310 (6.29)     293 (6.24)     17 (7.23)
  **Brain metastases**                                                                        
   Yes                                        89 (1.46)         128 (2.60)     126 (2.68)     2 (0.85)
   No                                         5705 (93.46)      4468 (90.59)   4254 (90.57)   214 (91.06)
   Others                                     310 (5.08)        336 (6.81)     317 (6.75)     19 (8.09)
  **Surgery**                                                                                 
   Yes                                        861 (14.11)       275 (5.58)     254 (5.41)     21 (8.94)
   No                                         123 (2.02)        133 (2.70)     128 (2.73)     5 (2.13)
   Unknown                                    5120 (83.88)      4524 (91.73)   4315 (91.87)   209 (88.94)

  Factors                                     Total early death                Cancer-specific early death             Non-cancer-specific early death   
  ------------------------------------------- ---------------------- --------- ----------------------------- --------- --------------------------------- ---------
  **Age**                                                                                                                                                
   ≤55                                        Ref                    1         Ref                           1         Ref                               1
   56--65                                     1.315 (1.184--1.461)   \<0.001   0.889 (0.771--1.024)          0.103     1.904 (1.226--3.014)              0.005
   66--75                                     1.759 (1.579--1.960)   \<0.001   0.981 (0.845--1.140)          0.802     2.791 (1.183--4.357)              \<0.001
   ≥76                                        3.362 (3.009--3.759)   \<0.001   1.474 (1.249--1.743)          \<0.001   3.482 (2.309--5.391)              \<0.001
  **Race**                                                                                                                                               
   White                                      Ref                    1         Ref                           1         Ref                               1
   Black                                      1.162 (1.040--1.299)   0.008     1.030 (0.876--1.216)          0.726     1.285 (0.895--1.803)              0.159
   Asian or Pacific Islander                  0.868 (0.775--0.971)   0.014     0.860 (0.737--1.007)          0.058     0.870 (0.565--1.288)              0.506
   American Indian/Alaska Native              1.188 (0.844--1.670)   0.322     1.598 (0.919--3.060)          0.123     0.346 (0.020--1.558)              0.292
   Unknown                                    NA                     NA        NA                            NA        NA                                NA
  **Sex**                                                                                                                                                
   Female                                     Ref                    1         Ref                           1         Ref                               1
   Male                                       0.982 (0.908--1.062)   0.646     0.913 (0.814--1.023)          0.12      1.043 (0.798--1.373)              0.76
  **Marital status**                                                                                                                                     
   Unmarried                                  Ref                    1         Ref                           1         Ref                               1
   Married                                    0.627 (0.580--0.678)   \<0.001   0.863 (0.769--0.967)          0.012     0.735 (0.564--0.959)              0.023
   Unknown                                    NA                     NA        NA                            NA        NA                                NA
  **Insurance status**                                                                                                                                   
   Uninsured                                  Ref                    1         Ref                           1         Ref                               1
   Insured                                    0.765 (0.646--0.905)   0.002     0.923 (0.712--1.179)          0.533     2.067 (1.000--5.261)              0.081
   Unknown                                    NA                     NA        NA                            NA        NA                                NA
  **Primary site**                                                                                                                                       
   Non-cardia                                 Ref                    1         Ref                           1         Ref                               1
   Cardia                                     0.758 (0.695--0.827)   \<0.001   0.998 (0.885--1.127)          0.98      0.811 (0.593--1.099)              0.183
   Unknown                                    NA                     NA        NA                            NA        NA                                NA
  **Pathological type**                                                                                                                                  
   Adenocarcinoma(exclude signet ring cell)   Ref                    1         Ref                           1         Ref                               1
   Signet ring cell                           0.924 (0.841--1.014)   0.097     1.187 (1.035--1.366)          0.015     0.795 (0.555--1.114)              0.196
   Others                                     NA                     NA        NA                            NA        NA                                NA
  **Tumor size (cm)**                                                                                                                                    
   \<3                                        Ref                    1         Ref                           1         Ref                               1
   ≥3 \<5                                     1.078 (0.890--1.309)   0.443     1.288 (1.015--1.631)          0.036     1.140 (0.589--2.310)              0.704
   ≥5 \<7                                     1.096 (0.903--1.331)   0.354     1.416 (1.111--1.802)          0.005     0.885 (0.438--1.844)              0.736
   ≥7 \<9                                     1.085 (0.864--1.362)   0.481     1.455 (1.090--1.951)          0.012     1.128 (0.503--2.506)              0.765
   ≥9                                         1.375 (1.100--1.718)   0.005     1.787 (1.326--2.426)          \<0.001   1.001 (0.436--2.254)              0.999
   Unknown                                    NA                     NA        NA                            NA        NA                                NA
  **T stage**                                                                                                                                            
   T1                                         Ref                    1         Ref                           1         Ref                               1
   T2                                         0.622 (0.505--0.765)   \<0.001   0.710 (0.545--0.933)          0.0126    0.410 (0.157--0.889)              0.041
   T3                                         0.544 (0.470--0.629)   \<0.001   0.712 (0.587--0.863)          \<0.001   0.533 (0.318--0.867)              0.013
   T4                                         0.906 (0.799--1.027)   0.122     1.024 (0.850--1.231)          0.804     0.630 (0.414--0.953)              0.029
   Others                                     NA                     NA        NA                            NA        NA                                NA
  **Lymphatic metastasis**                                                                                                                               
   N0                                         Ref                    1         Ref                           1         Ref                               1
   N1                                         0.673 (0.614--0.738)   \<0.001   0.921 (0.808--1.050)          0.22      0.766 (0.559--1.046)              0.095
   N2                                         0.474 (0.396--0.565)   \<0.001   0.587 (0.476--0.728)          \<0.001   0.626 (0.305--1.150)              0.163
   N3                                         0.477 (0.401--0.565)   \<0.001   0.696 (0.564--0.865)          \<0.001   0.513 (0.240--0.966)              0.057
   Others                                     NA                     NA        NA                            NA        NA                                NA
  **Histological grade**                                                                                                                                 
   I                                          Ref                    1         Ref                           1         Ref                               1
   II                                         1.392 (1.005--1.950)   0.05      1.715 (1.187--2.437)          0.003     1.513 (0.547--6.272)              0.491
   III                                        1.755 (1.280--2.437)   \<0.001   2.237 (1.568--3.134)          \<0.001   1.018 (0.379--4.163)              0.976
   IV                                         2.540 (1.616--4.023)   \<0.001   2.867 (1.555--5.550)          0.001     0.831 (0.108--5.080)              0.84
   Others                                     NA                     NA        NA                            NA        NA                                NA
  **Liver metastases**                                                                                                                                   
   Yes                                        Ref                    1         Ref                           1         Ref                               1
   No                                         0.697 (0.645--0.753)   \<0.001   0.822 (0.735--0.920)          \<0.001   0.699 (0.535--0.911)              0.008
   Others                                     NA                     NA        NA                            NA        NA                                NA
  **Lung metastases**                                                                                                                                    
   Yes                                        Ref                    1         Ref                           1         Ref                               1
   No                                         0.636 (0.572--0.708)   \<0.001   0.797 (0.676--0.935)          0.006     0.662 (0.483--0.925)              0.013
   Others                                     NA                     NA        NA                            NA        NA                                NA
  Bone metastases                                                                                                                                        
   Yes                                        Ref                    1         Ref                           1         Ref                               1
   No                                         0.684 (0.611--0.766)   \<0.001   0.561 (0.461--0.677)          \<0.001   1.110 (0.753--1.704)              0.616
   Others                                     NA                     NA        NA                            NA        NA                                NA
  **Brain metastases**                                                                                                                                   
   Yes                                        Ref                    1         Ref                           1         Ref                               1
   No                                         0.545 (0.413--0.714)   \<0.001   0.760 (0.483--1.142)          0.209     2.310 (0.734--14.004)             0.241
   Others                                     NA                     NA        NA                            NA        NA                                NA
  **Surgery**                                                                                                                                            
   Yes                                        Ref                    1         Ref                           1         Ref                               1
   No                                         3.385 (2.559--4.485)   \<0.001   3.132 (2.054--4.986)          \<0.001   1.058 (0.350--2.624)              0.911
   Unknown                                    NA                     NA        NA                            NA        NA                                NA

Ref -- reference; OR -- odds ratio; NA -- not available.

###### 

Multivariable logistic regression for analyzing the risk factors for early death.

  Factors                                     Total early death         Cancer-specific early death   Non-cancer-specific early death                                  
  ------------------------------------------- ------------------------- ----------------------------- --------------------------------- ------- ---------------------- ---------
  **Age**                                                                                                                                                              
   ≤55                                        Ref                       1                             Ref                               1       Ref                    1
   56--65                                     0.853 (0.436--1.582)      0.582                         0.931 (0.551--1.575)              0.787   1.879 (1.208--2.979)   0.17
   66--75                                     3.252 (1.827--5.899)      \<0.001                       1.050 (0.607--1.828)              0.863   2.729 (1.785--4.273)   \<0.001
   ≥76                                        3.441 (1.927--6.265)      \<0.001                       1.333 (0.747--2.410)              0.335   3.258 (2.154--5.059)   \<0.001
  **Race**                                                                                                                                                             
   White                                      Ref                       1                             Ref                               1       Ref                    1
   Black                                      1.081 (0.600--1.909)      0.792                         NS                                NS      NS                     NS
   Asian or Pacific Islander                  0.615 (0.356--1.033)      0.073                         NS                                NS      NS                     NS
   American Indian/Alaska Native              1.886 (0.116--25.241)     0.632                         NS                                NS      NS                     NS
   Unknown                                    NA                        NA                            NA                                NA      NA                     NA
  **Sex**                                                                                                                                                              
   Female                                     Ref                       1                             1                                 1       Ref                    1
   Male                                       NS                        NS                            NS                                NS      NS                     NS
  **Marital status**                                                                                                                                                   
   Unmarried                                  Ref                       1                             Ref                               1       Ref                    1
   Married                                    0.724 (0.474--1.108)      0.136                         1.007 (0.664--1.518)              0.972   0.754 (0.577--0.987)   0.13
   Unknown                                    NA                        NA                            NA                                NA      NA                     NA
  **Insurance status**                                                                                                                                                 
   Uninsured                                  Ref                       1                             Ref                               1       Ref                    1
   Insured                                    1.719 (0.624--6.101)      0.34                          NS                                NS      NS                     NS
   Unknown                                    NA                        NA                            NA                                NA      NA                     NA
  **Primary site**                                                                                                                                                     
   Non-cardia                                 Ref                       1                             Ref                               1       Ref                    1
   Cardia                                     0.307 (0.138--0.627)      0.002                         NS                                NS      NS                     NS
   Unknown                                    NA                        NA                            NA                                NA      NA                     NA
  **Pathological type**                                                                                                                                                
   Adenocarcinoma(exclude signet ring cell)   Ref                       1                             Ref                               1       Ref                    1
   Signet ring cell                           NS                        NS                            1.023 (0.616--1.715)              0.93    NS                     NS
   Others                                     NA                        NA                            NA                                NA      NA                     NA
  **Tumor size (cm)**                                                                                                                                                  
   \<3                                        Ref                       1                             Ref                               1       Ref                    1
   ≥3 \<5                                     0.850 (0.392--1.902)      0.685                         1.456 (0.765--2.749)              0.248   NS                     NS
   ≥5 \<7                                     0.693 (0.318--1.558)      0.364                         1.435 (0.741--2.754)              0.28    NS                     NS
   ≥7 \<9                                     1.104 (0.484--2.583)      0.817                         1.842 (0.895--3.809)              0.097   NS                     NS
   ≥9                                         0.916 (0.401--2.145)      0.836                         2.414 (1.114--5.333)              0.027   NS                     NS
   Unknown                                    NA                        NA                            NA                                NA      NA                     NA
  **T stage**                                                                                                                                                          
   T1                                         Ref                       1                             Ref                               1       Ref                    1
   T2                                         0.395 (0.073--1.713)      0.237                         0.968 (0.338--2.775)              0.952   0.443 (0.169--0.966)   0.113
   T3                                         1.076 (0.405--3.062)      0.886                         1.698 (0.713--4.002)              0.226   0.581 (0.346--0.949)   0.076
   T4                                         1.726 (0.656--4.882)      0.283                         2.287 (0.951--5.440)              0.061   0.693 (0.455--1.052)   0.155
   Others                                     NA                        NA                            NA                                NA      NA                     NA
  **Lymphatic metastasis**                                                                                                                                             
   N0                                         Ref                       1                             Ref                               1       Ref                    1
   N1                                         0.711 (0.349--1.448)      0.345                         0.991 (0.531--1.834)              0.977   NS                     NS
   N2                                         0.649 (0.312--1.351)      0.246                         1.587 (0.822--3.061)              0.167   NS                     NS
   N3                                         0.819 (0.427--1.600)      0.552                         1.524 (0.820--2.796)              0.177   NS                     NS
   Others                                     NA                        NA                            NA                                NA      NA                     NA
  **Histological grade**                                                                                                                                               
   I                                          Ref                       1                             Ref                               1       Ref                    1
   II                                         3.591 (0.586--70.424)     0.25                          2.339 (0.689--8.178)              0.171   NS                     NS
   III                                        6.768 (1.149--131.038)    0.082                         3.363 (1.011--11.525)             0.047   NS                     NS
   IV                                         11.195 (1.438--240.700)   0.044                         7.594 (1.302--64.796)             0.035   NS                     NS
   Others                                     NA                        NA                            NA                                NA      NA                     NA
  **Liver metastases**                                                                                                                                                 
   Yes                                        Ref                       1                             Ref                               1       Ref                    1
   No                                         0.447 (0.285--0.699)      \<0.001                       0.564 (0.346--0.903)              0.019   0.822 (0.626--1.078)   0.667
   Others                                     NA                        NA                            NA                                NA      NA                     NA
  **Lung metastases**                                                                                                                                                  
   Yes                                        Ref                       1                             Ref                               1       Ref                    1
   No                                         0.223 (0.102--0.485)      \<0.001                       0.642 (0.255--1.457)              0.314   0.723 (0.526--1.014)   0.027
   Others                                     NA                        NA                            NA                                NA      NA                     NA
  Bone metastases                                                                                                                                                      
   Yes                                        Ref                       1                             Ref                               1       Ref                    1
   No                                         0.813 (0.296--2.525)      0.701                         0.640 (0.178--1.800)              0.438   NS                     NS
   Others                                     NA                        NA                            NA                                NA      NA                     NA
  **Brain metastases**                                                                                                                                                 
   Yes                                        Ref                       1                             Ref                               1       Ref                    1
   No                                         0.125 (0.018--1.282)      0.051                         NS                                NS      NS                     NS
   Others                                     NA                        NA                            NA                                NA      NA                     NA
  **Surgery**                                                                                                                                                          
   Yes                                        Ref                       1                             Ref                               1       Ref                    1
   No                                         2.835 (1.005--7.888)      0.045                         11.912 (2.338--218.646)           0.018   NS                     NS
   Unknown                                    NA                        NA                            NA                                NA      NA                     NA

Ref -- reference; OR -- odds ratio; NA -- not available; NS -- not significant.
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